Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS

1. (Currently amended): A method of inhibiting the interaction of a first cell bearing a B7-2 receptor with a second cell bearing B7-2, comprising contacting said second cell with an effective amount of a humanized immunoglobulin having binding specificity for B7-2, said immunoglobulin comprising:

a) at least one antigen binding region of nonhuman origin and

b) ~~at least~~ a portion of an immunoglobulin heavy chain of human origin derived from the III2R (SEQ ID NOS: 25, 29) variable region and/~~or~~ ~~at least~~ a portion of an immunoglobulin light chain of human origin derived from the H2F (SEQ ID NOS: 26, 30) variable region,

wherein ~~the immunoglobulin has at least a portion of the amino acid sequence of its variable region in common with at least a portion of the amino acid sequence of the variable region of the III2R heavy chain (SEQ ID NOS: 25, 29) and/or the H2F light chain (SEQ ID NOS: 26, 30) antibody and~~ the humanized immunoglobulin has a binding affinity of at least about 10^7 M^{-1}.

2. (Currently amended): A method of inducing immunotolerance in a patient having a transplanted organ, tissue, cell, or the like comprising administering an

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

effective amount of a humanized immunoglobulin having binding specificity for B7-2, said immunoglobulin comprising:

a) at least one antigen binding region of nonhuman origin, and

b) ~~at least~~ a portion of an immunoglobulin heavy chain of human origin derived from the III2R (SEQ ID NOS: 25, 29) variable region and/~~or at least~~ a portion of an immunoglobulin light chain of human origin derived from the H2F (SEQ ID NOS: 26, 30) variable region,

wherein the immunoglobulin is administered in a carrier~~, and wherein the immunoglobulin has at least a portion of the amino acid sequence of its variable region in common with at least a portion of the amino acid sequence of the variable region of the III2R (SEQ ID NOS: 25, 29) and/or the H2F (SEQ ID NOS: 26, 30) antibody~~ and the humanized antibody has a binding affinity of at least about 10^7 M^{-1}.

3. (Currently amended): A method of reducing transplantation rejection in a patient having a transplanted organ, tissue, or cell, comprising administering a therapeutically effective amount of a humanized ~~antibody~~ immunoglobulin having binding specificity for B7-2, said immunoglobulin comprising:

a) at least one antigen binding region of nonhuman origin, and

b) ~~at least~~ a portion of an immunoglobulin heavy chain of human origin derived from the III2R (SEQ ID NOS: 25, 29) variable region and/~~or~~ a portion of an immunoglobulin light chain of human origin derived from the H2F (SEQ ID NOS: 26, 30) variable region,

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

wherein ~~the immunoglobulin has at least a portion of the amino acid sequence of its variable region in common with at least a portion of the amino acid sequence of the variable region of the III2R (SEQ ID NOS: 25, 29) and/or the H2F (SEQ ID NOS: 26, 30) antibody~~ and the humanized immunoglobulin has a binding affinity of at least about 10^7 M^{-1}.

4. (Original): The method of claim 2, wherein the carrier is pharmaceutical carrier.

5. (Withdrawn): A method of modulating an immune response of a patient having a transplanted organ, tissue, cell or the like comprising administering an effective amount of a humanized immunoglobulin specific to B7-1 and an effective amount of a humanized immunoglobulin specific to B7-2 in a carrier.

6. (Currently amended): The method of claim 1, wherein said at least one antigen binding region further comprises ~~at least~~ one CDR of the variable region of the 3D1 (SEQ ID NOS: 21, 23) antibody.

7. (Previously presented): The method of claim 1, wherein said immunoglobulin comprises a light chain encoded by the amino acid sequence of SEQ ID NO: 8 and a heavy chain encoded by the amino acid sequence of SEQ ID NO: 6.

8. (Previously presented): The method of claim 7, wherein said immunoglobulin further comprises a constant region comprising a human IgG4 isotype.

9. (Previously presented): The method of claim 7, wherein said immunoglobulin further comprises a constant region comprising a human IgG2M3 isotype.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

10. (Currently amended): The method of claim 1, wherein said immunoglobulin has ~~at least~~ a portion of the amino acid sequence of its variable region in common with ~~at least~~ a portion of the amino acid sequence of the variable region of the III2R (SEQ ID NOS: 25, 29) heavy chain ~~antibody~~.

11. (Currently amended): The method of claim 1, wherein said immunoglobulin has ~~at least~~ a portion of the amino acid sequence of its variable region in common with ~~at least~~ a portion of the amino acid sequence of the variable region of the H2F (SEQ ID NOS: 26, 30) light chain ~~antibody~~.

12. (Currently amended): The method of claim 2, wherein said at least one antigen binding region further comprises ~~at least~~ one CDR ~~of the variable region~~ of the variable region of the 3D1 (SEQ ID NOS: 21, 23) antibody.

13. (Previously presented): The method of claim 2, wherein said immunoglobulin comprises a light chain encoded by the amino acid sequence of SEQ ID NO: 8 and a heavy chain encoded by the amino acid sequence of SEQ ID NO: 6.

14. (Previously presented): The method of claim 13, wherein said immunoglobulin further comprises a constant region comprising a human IgG4 isotype.

15. (Previously presented): The method of claim 13, wherein said immunoglobulin further comprises a constant region comprising a human IgG2M3 isotype.

16. (Currently amended): The method of claim 2, wherein said immunoglobulin has ~~at least~~ a portion of the amino acid sequence of its variable region

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

in common with ~~at least~~ a portion of the amino acid sequence of the variable region of the III2R (SEQ ID NOS: 25, 29) heavy chain ~~antibody~~.

17. (Currently amended): The method of claim 2, wherein said immunoglobulin has ~~at least~~ a portion of the amino acid sequence of its variable region in common with ~~at least~~ a portion of the amino acid sequence of the variable region of the H2F (SEQ ID NOS: 26, 30) light chain ~~antibody~~.

18. (Currently amended): The method of claim 3, wherein said at least one antigen binding region further comprises ~~at least~~ one CDR of the variable region of 3D1 antibody.

19. (Previously presented): The method of claim 3, wherein said immunoglobulin comprises a light chain encoded by the amino acid sequence of SEQ ID NO: 8 and a heavy chain encoded by the amino acid sequence of SEQ ID NO: 6.

20. (Currently amended): The method of claim 19, wherein said immunoglobulin further comprises a constant region ~~comprises~~ comprising a human IgG4 isotype.

21. (Previously presented): The method of claim 19, wherein said immunoglobulin further comprises a constant region ~~comprises~~ comprising a human IgG2M3 isotype.

22. (Currently amended): The method of claim 3, wherein said immunoglobulin has ~~at least~~ a portion of the amino acid sequence of its variable region in common with ~~at least~~ a portion of the amino acid sequence of the variable region of the III2R (SEQ ID NOS: 25, 29) heavy chain ~~antibody~~.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

23. (Currently amended): The method of claim 3, wherein said immunoglobulin has ~~at least~~ a portion of the amino acid sequence of its variable region in common with ~~at least~~ a portion of the amino acid sequence of the variable region of the H2F (SEQ ID NOS: 26, 30) light chain ~~antibody~~.

24. (Previously presented): The method of claim 1, wherein the binding affinity is about $10^9\ M^{-1}$.

25. (Previously presented): The method of claim 2, wherein the binding affinity is about $10^9\ M^{-1}$.

26. (Previously presented): The method of claim 3, wherein the binding affinity is about $10^9\ M^{-1}$.

27. (New): A method of inhibiting the interaction of a first cell bearing a B7-2 receptor with a second cell bearing B7-2, comprising contacting said second cell with an effective amount of a humanized immunoglobulin having binding specificity for B7-2, said immunoglobulin comprising:

a) a light chain which comprises one or more CDR's derived from an antibody of non-human origin which binds to B7-2 and a framework region derived from a human H2F antibody (SEQ ID NOS: 26, 30); and

b) a heavy chain which comprises one or more CDR's derived from an antibody of non-human origin which binds to B7-2 and a framework region derived from the human III2R antibody (SEQ ID NOS: 25, 29).

28. (New): The method of claim 27, wherein said one or more CDRs are derived from the variable region of the 3D1 (SEQ ID NOS: 21, 23) antibody.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

29. (New): The method of claim 27, wherein said light chain comprises three CDRs derived from an antibody of non-human origin which binds B7-2 and a framework region derived from a human H2F antibody (SEQ ID NOS: 26, 30) and said heavy chain comprises three CDRs derived from an antibody of non-human origin which binds B7-2 and a framework region derived from the human III2R antibody (SEQ ID NOS: 25, 29).

30. (New): The method of claim 27, wherein said immunoglobulin comprises a light chain encoded by the amino acid sequence of SEQ ID NO: 8 and a heavy chain encoded by the amino acid sequence of SEQ ID NO: 6.

31. (New): The method of claim 27, wherein said immunoglobulin further comprises a constant region comprising a human IgG4 isotype.

32. (New): The method of claim 27, wherein said immunoglobulin further comprises a constant region comprising a human IgG2M3 isotype.

33. (New): The method of claim 27, wherein the binding affinity is about 10^9 M^{-1}.

34. (New) A method of inducing immunotolerance in a patient having a transplanted organ, tissue, cell, or the like comprising administering an effective amount of a humanized immunoglobulin having binding specificity for B7-2, said immunoglobulin comprising:

a) a light chain which comprises one or more CDR's derived from an antibody of non-human origin which binds to B7-2 and a framework region derived from a human H2F antibody (SEQ ID NOS: 26, 30); and

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

b) a heavy chain which comprises one or more CDR's derived from an antibody of non-human origin which binds to B7-2 and a framework region derived from the human III2R antibody (SEQ ID NOS: 25, 29).

35. (New): The method of claim 34, wherein said one or more CDRs are derived from the variable region of the 3D1 (SEQ ID NOS: 21, 23) antibody.

36. (New): The method of claim 34, wherein said light chain comprises three CDRs derived from an antibody of non-human origin which binds B7-2 and a framework region derived from a human H2F antibody (SEQ ID NOS: 26, 30) and said heavy chain comprises three CDRs derived from an antibody of non-human origin which binds B7-2 and a framework region derived from the human III2R antibody (SEQ ID NOS: 25, 29).

37. (New): The method of claim 34, wherein said immunoglobulin comprises a light chain encoded by the amino acid sequence of SEQ ID NO: 8 and a heavy chain encoded by the amino acid sequence of SEQ ID NO: 6.

38. (New): The method of claim 34, wherein said immunoglobulin further comprises a constant region comprising a human IgG4 isotype.

39. (New): The method of claim 34, wherein said immunoglobulin further comprises a constant region comprising a human IgG2M3 isotype.

40. (New): The method of claim 34, wherein the binding affinity is about 10^9 M^{-1}.

41. (New) A method of reducing transplantation rejection in a patient having a transplanted organ, tissue, or cell, comprising administering a therapeutically effective

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

amount of a humanized immunoglobulin having binding specificity for B7-2, said immunoglobulin comprising:

a) a light chain which comprises one or more CDR's derived from an antibody of non-human origin which binds to B7-2 and a framework region derived from a human H2F antibody (SEQ ID NOS: 26, 30); and

b) a heavy chain which comprises one or more CDR's derived from an antibody of non-human origin which binds to B7-2 and a framework region derived from the human III2R antibody (SEQ ID NOS: 25, 29).

42. (New): The method of claim 41, wherein said one or more CDRs are derived from the variable region of the 3D1 (SEQ ID NOS: 21, 23) antibody.

43. (New): The method of claim 41, wherein said light chain comprises three CDRs derived from an antibody of non-human origin which binds B7-2 and a framework region derived from a human H2F antibody (SEQ ID NOS: 26, 30) and said heavy chain comprises three CDRs derived from an antibody of non-human origin which binds B7-2 and a framework region derived from the human III2R antibody (SEQ ID NOS: 25, 29).

44. (New): The method of claim 41, wherein said immunoglobulin comprises a light chain encoded by the amino acid sequence of SEQ ID NO: 8 and a heavy chain encoded by the amino acid sequence of SEQ ID NO: 6.

45. (New): The method of claim 41, wherein said immunoglobulin further comprises a constant region comprising a human IgG4 isotype.

46. (New): The method of claim 41, wherein said immunoglobulin further comprises a constant region comprising a human IgG2M3 isotype.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

47. (New): The method of claim 41, wherein the binding affinity is about 10^9 M^{-1}.

48. (New) The method of claim 1, wherein the portion of an immunoglobulin light chain of human origin derived from the H2F (SEQ ID NOS: 26, 30) variable region is the framework region.

49. (New) The method of claim 1, wherein the portion of an immunoglobulin heavy chain of human origin derived from the III2R (SEQ ID NOS: 25, 29) variable region is the framework region.

50. (New) The method of claim 2, wherein the portion of an immunoglobulin light chain of human origin derived from the H2F (SEQ ID NOS: 26, 30) variable region is the framework region.

51. (New) The method of claim 2, wherein the portion of an immunoglobulin heavy chain of human origin derived from the III2R (SEQ ID NOS: 25, 29) variable region is the framework region.

52. (New) The method of claim 3, wherein the portion of an immunoglobulin light chain of human origin derived from the H2F (SEQ ID NOS: 26, 30) variable region is the framework region.

53. (New) The method of claim 3, wherein the portion of an immunoglobulin heavy chain of human origin derived from the III2R (SEQ ID NOS: 25, 29) variable region is the framework region.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

54. (New) The method of claim 1, wherein said at least one antigen binding region further comprises two CDRs of the variable region of the 3D1 (SEQ ID NOS: 21, 23) antibody.

55. (New) The method of claim 1, wherein said at least one antigen binding region further comprises three CDRs of the variable region of the 3D1 (SEQ ID NOS: 21, 23) antibody.

56. (New) The method of claim 2, wherein said at least one antigen binding region further comprises two CDRs of the variable region of the 3D1 (SEQ ID NOS: 21, 23) antibody.

57. (New) The method of claim 2, wherein said at least one antigen binding region further comprises three CDRs of the variable region of the 3D1 (SEQ ID NOS: 21, 23) antibody.

58. (New) The method of claim 3, wherein said at least one antigen binding region further comprises two CDRs of the variable region of the 3D1 (SEQ ID NOS: 21, 23) antibody.

59. (New) The method of claim 3, wherein said at least one antigen binding region further comprises three CDRs of the variable region of the 3D1 (SEQ ID NOS: 21, 23) antibody.

60. (New) A method of inhibiting the interaction of a first cell bearing a B7-2 receptor with a second cell bearing B7-2, comprising contacting said second cell with an effective amount of a humanized immunoglobulin having binding specificity for B7-2, said immunoglobulin comprising:

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

a) at least one antigen binding region of nonhuman origin and

b) a portion of an immunoglobulin heavy chain of human origin derived from the III2R (SEQ ID NOS: 25, 29) or a portion of an immunoglobulin light chain of human origin derived from the H2F (SEQ ID NOS: 26, 30) variable region-and the humanized immunoglobulin has a binding affinity of at least about $10^7 M^{-1}$.

61. (New) A method of inducing immunotolerance in a patient having a transplanted organ, tissue, cell, or the like comprising administering an effective amount of a humanized immunoglobulin having binding specificity for B7-2, said immunoglobulin comprising:

a) at least one antigen binding region of nonhuman origin, and

b) a portion of an immunoglobulin heavy chain of human origin derived from the III2R (SEQ ID NOS: 25, 29) or a portion of an immunoglobulin light chain of human origin derived from the H2F (SEQ ID NOS: 26, 30) variable region, wherein the immunoglobulin is administered in a carrier, and the humanized antibody has a binding affinity of at least about $10^7 M^{-1}$.

62. (New) A method of reducing transplantation rejection in a patient having a transplanted organ, tissue, or cell, comprising administering a therapeutically effective amount of a humanized antibody having binding specificity for B7-2, said immunoglobulin comprising:

a) at least one antigen binding region of nonhuman origin, and

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

b) a portion of an immunoglobulin heavy chain of human origin derived from the III2R (SEQ ID NOS: 25, 29) or a portion of an immunoglobulin light chain of human origin derived from the H2F (SEQ ID NOS: 26, 30) variable region-and the humanized immunoglobulin has a binding affinity of at least about $10^7 M^{-1}$.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com